Investigational drug · Phase 2
DS-7011a
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Systemic Lupus Erythematosus.
Phase 2Last checked: Nov 19, 2026Latest source record: May 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "DS-7011a"
First trial start
2023
Jun 7, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DS-7011a", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "DS-7011a" as an intervention, largest first.
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT05203692 · 80 participants · Start Feb 2, 2022 · Primary completion Jan 25, 2023
Drug: DS-7011a; Placebo · For: Systemic Lupus Erythematosus
Sites: Long Beach, California; San Antonio, Texas
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT05638802 · 26 participants · Start Jun 7, 2023 · Primary completion Apr 1, 2025
Drug: DS-7011a; Placebo · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; North Little Rock, Arkansas; North Miami Beach, Florida · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Anti-human TLR7 antibody for therapeutic intervention in systemic lupus erythematosus.
Fukui R, Murakami Y, Kanno A, et al. · Int Immunol 2026
- Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review.
Kaye AD, Tassin JP, Upshaw WC, et al. · Cureus 2024
- First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus.
Senaldi G, Mohan A, Zhang L, et al. · J Clin Pharmacol 2024
Also in development for Systemic Lupus Erythematosus
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- EnpatoranM5049, M5049 dosePhase 35 trials
EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
- MIL62Phase 34 trials
Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy
- ObexelimabPhase 34 trials
Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Daiichi Sankyo.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.